Estrogen-Progestogen Therapy (EPT)
Treatment for Menopause
Typical Dosage: Oral Estradiol 0.5-1mg daily with progestogen (e.g., Micronized Progesterone 100-200mg daily or cyclically)
Effectiveness
90%
Safety Score
60%
Clinical Trials
1
Participants
500K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Oral Estradiol 0.5-1mg daily with progestogen (e.g., Micronized Progesterone 100-200mg daily or cyclically)
Time to Effect
1-4 weeks
Treatment Duration
2-5 years, reassess
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$500
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$875
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$45,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$1,029.41
Cost per Remission
$1,346.15
Estrogen-Progestogen Therapy (EPT) Outcomes
for Menopause
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+85%
Remission Rate
+65%
Common Side Effects
Breast tenderness
+25%
Nausea
+8%
Headache
+12%
Vaginal bleeding/spotting
+15%
Bloating
+10%
Increased risk of VTE
+0.03%
Increased risk of breast cancer (long-term use)
+0.05%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Estrogen-Progestogen Therapy (EPT) in Menopause
Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.
NCT03921736COMPLETEDPHASE4
180 participants
INTERVENTIONAL
Started: Jan 10, 2000